decisionhealth Newsletters, Coder Pink Sheets - 2009 Issue 1 (January)
Chemotherapy codes include ‘highly complex’ drugs
Subscribe or sign in to view the full article.
Article Overview
This piece is for medical coders, billing staff, and payers who need to understand how the chemotherapy administration section was broadened for 2009. It covers the revised section title, the scope of the updated guidelines, and the general category of drugs and biologic agents now included under the broader administration framework.
Why This Topic Matters
It matters because the change affects how providers and payers interpret an existing administration code family for non-cancer drugs with complex or toxic characteristics.
Article Sections
-
2009 chemotherapy administration update
Overview of the 2009 revision to the chemotherapy administration section and the broader category now reflected in the section title.
-
Guideline language and scope
Discussion of the guideline wording associated with the affected code family and the types of parenteral drug administration referenced in the article.
-
Practical impact for providers and payers
General explanation of why the revision may affect coding interpretation for non-cancer medications with complex administration characteristics.
What You Will Learn
- What changed in the chemotherapy administration section for 2009
- Which general type of code family the article discusses
- How the article frames the broadened scope of the administration guidelines
- Why the update may matter to providers and payers
Who Should Read This
- Medical coders
- Billing professionals
- Compliance staff
- Payers
- Revenue cycle teams
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com